论文部分内容阅读
目的探讨金属蛋白酶抑制基因RECK在肝细胞癌(hepatocellular carcinoma,HCC)中的表达及其临床意义。方法用实时逆转录聚合酶链反应(real-time RT-PCR)技术和免疫组化方法分别检测61例HCC、癌旁组织及18例正常肝组织中RECK mRNA和蛋白表达情况。结果 RECK mRNA在HCC中表达水平(0.0269±0.0026)低于癌旁肝组织(0.0378±0.0031,P<0.05)。RECK蛋白在HCC组织中阳性表达率(59.0%)也显著低于癌旁肝组织(78.7%,P<0.05)。RECK在HCC组织中的阳性检出率与肿瘤大小、是否复发、有无门脉癌栓、肿瘤有无完整包膜等临床因素显著相关(P<0.05),而与年龄、性别、有无肝硬化、乙肝表面抗原、AFP水平等无关。对61例患者的随访资料进行生存分析显示,RECK阳性组3年生存率83.9%,明显高于RECK阴性组52.1%(P<0.05)。结论 RECK可能参与HCC的发生发展,有可能成为预测HCC浸润与转移的参考指标。
Objective To investigate the expression of RECK in human hepatocellular carcinoma (HCC) and its clinical significance. Methods Real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry were used to detect the expression of RECK mRNA and protein in 61 cases of HCC, adjacent non-cancerous tissues and 18 cases of normal liver tissues. Results The expression level of RECK mRNA in HCC (0.0269 ± 0.0026) was lower than that in para-cancerous liver tissue (0.0378 ± 0.0031, P <0.05). The positive expression rate of RECK protein in HCC tissues (59.0%) was also significantly lower than that in paracancer liver tissues (78.7%, P <0.05). The positive detection rate of RECK in HCC tissues was significantly correlated with tumor size, recurrence, portal vein tumor thrombus, complete tumor capsule and other clinical factors (P <0.05), but not with age, gender, Sclerosis, hepatitis B surface antigen, AFP level has nothing to do. Survival analysis of 61 patients with follow-up data showed that the 3-year survival rate of RECK positive group was 83.9%, significantly higher than that of RECK negative group (52.1%, P <0.05). Conclusions RECK may be involved in the development of HCC, which may become a reference index for predicting the invasion and metastasis of HCC.